Cover -- Half Title -- Series Page -- Title Page -- Copyright Page -- Table of Contents -- List of Figures -- List of Tables -- List of Contributors -- List of Abbreviations -- Introduction -- 1: Inflammation in Cardio-Oncology -- 1.1 Introduction -- 1.2 Inflammation in Cardiac Injury and Repair -- 1.3 Immune Checkpoint Inhibitors -- 1.4 CAR-T Cell Therapy -- 1.5 Inflammation at the Crossroad Between Cancer and Cardiovascular Diseases -- References -- 2: Vascular Toxicity and Thromboembolic Risk in Cardio-Oncology -- 2.1 Introduction -- 2.2 Acute Coronary Syndrome (ACS) and Coronary Artery Diseases (CAD) -- 2.3 Other Drugs that Cause Myocardial Infarction and Coronary Artery Diseases -- 2.4 Arterial Hypertension -- 2.5 Peripheral Artery Occlusive Diseases -- 2.6 Pulmonary Hypertension -- 2.7 Stroke -- 2.8 Thromboembolic Risk and Atrial Fibrillation -- 2.9 Prevention and Treatment of Vascular Toxicity -- References -- 3: Hypertensive Oncologic Patients -- 3.1 Introduction -- 3.2 Implications of Arterial Hypertension in Patients Undergoing Anticancer Treatments -- 3.2.1 Anthracyclines -- 3.2.2 Carfilzomib -- 3.2.3 Anti-Vascular Endothelial Growth Factor Agents -- 3.3 Management of Arterial Hypertension in Oncologic Patients -- References -- 4: Cardiac Surgery and Percutaneous Coronary Intervention in Patients With Cancer -- 4.1 Introduction -- 4.1.1 The Complex Interplay Between ACS and Cancer: Bench and Pharmacological Data -- 4.1.2 The Complex Interplay between ACS and Cancer: The Role of the Disease -- 4.1.3 The Complex Interplay between ACS and Cancer: The Role of Chemotherapy and of Radiotherapy -- 4.1.4 The Complex Interplay between ACS and Cancer: Clinical Data -- 4.1.5 The Complex Interplay between Cardiac Surgery and Cancer: Clinical Data -- References -- 5: Cancer Therapy-Induced Arrhythmias -- 5.1 Introduction -- 5.1.1 Epidemiology.

5.1.2 Etiology and Pathogenesis -- 5.1.3 Diagnosis, Physical Examination, and Diagnostic Tests -- 5.1.4 Clinical Characteristics -- 5.1.5 Treatment -- 5.1.6. Prophylaxis -- References -- 6: Cancer in the Heart Failure Population -- 6.1 Introduction -- 6.2 Heart Failure and New Onset Cancer: Epidemiology -- 6.3 Mechanisms of Cancer Development in the Heart Failure Population -- 6.4 Cancer in Heart Failure Patients: Clinical Implications -- 6.5 Conclusions -- References -- 7: Metabolomics in the Identification of New Biomarkers in Cardio-Oncology -- 7.1 Introduction -- 7.2 Metabolomics -- 7.3 Metabolomics in Cardio-Oncology -- 7.4 Metabolomics Profiling Cardioprotective Strategies -- 7.5 Conclusion -- References -- 8: Imaging in Cardio-Oncology -- 8.1 Introduction -- 8.2 Conventional Echocardiography -- 8.2.1 LV Systolic and Diastolic Function -- 8.2.2 RV Function -- 8.2.3 Valvular Heart Disease -- 8.2.4 Pericardial Disease -- 8.3 Advanced Echocardiography -- 8.3.1 Myocardial Deformation Imaging -- 8.4 Three-Dimensional Echocardiography (3DE) -- 8.5 Assessment of Cardiotoxicity Risk and Echocardiographic Surveillance According to Anticancer Treatment -- 8.6 Other imaging modalities -- 8.6.1 Cardiac Magnetic Resonance -- 8.7 Cardiac Nuclear Imaging -- 8.8 Multimodality Imaging in Screening and Follow-Up in Radiotherapy -- 8.8.1 Pericardial disease -- 8.8.2 Myocardial dysfunction -- 8.8.3 Valvular Heart Disease (See also Above) -- 8.8.4 Coronary Artery Disease -- 8.9 Conclusions and Future Directions -- References -- 9: Venous Thromboembolism in Cardio-Oncology -- 9.1 Introduction -- 9.2 Biological Mechanism of Cancer-Related Thrombosis -- 9.3 Epidemiology and Risk Stratification -- 9.4 Clinical Presentation -- 9.5 Recurrent Venous Thrombosis and Treatment in Cancer Population -- 9.6 Prognosis -- 9.7 Thromboprophylaxis -- 9.8 Conclusions -- References.

Conclusions and Remarks -- References -- Index -- About the Editors.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2022. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.